Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Tigermed Reports 2023 Interim Results 2023-08-25 18:39
Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea 2023-08-25 18:19
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics 2023-08-25 15:14
Laekna, Inc. (2105.HK) Announces Interim Results 2023 2023-08-25 08:00
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA 2023-08-24 20:00
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor 2023-08-24 09:51
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs 2023-08-24 07:59
Complete Genomics Garners the Prestigious 2023 R&D 100 Awards for Cutting-Edge Innovation 2023-08-23 23:00
Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System 2023-08-23 18:00
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor 2023-08-23 10:51
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization 2023-08-22 20:58
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development 2023-08-22 20:00
CARsgen Announced 2023 Interim Results 2023-08-22 19:30
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China 2023-08-22 17:13
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model 2023-08-22 08:59
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023 2023-08-21 21:00
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer 2023-08-21 20:00
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study 2023-08-18 19:00
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements. 2023-08-18 08:58
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy 2023-08-17 21:00
1 42 43 44 45 46 222